699 related articles for article (PubMed ID: 23623245)
21. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
[TBL] [Abstract][Full Text] [Related]
22. Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients.
Intravooth T; Staack AM; Juerges K; Stockinger J; Steinhoff BJ
Epilepsy Res; 2018 Jul; 143():7-10. PubMed ID: 29631131
[TBL] [Abstract][Full Text] [Related]
23. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
24. [Eslicarbazepine acetate in clinical practice. Efficacy and safety results].
Serrano-Castro PJ; Payán-Ortiz M; Cimadevilla JM; Quiroga-Subirana P; Fernández-Pérez J
Rev Neurol; 2013 Mar; 56(6):309-14. PubMed ID: 23483464
[TBL] [Abstract][Full Text] [Related]
25. Eslicarbazepine acetate for partial-onset seizures.
Rauchenzauner M; Luef G
Expert Rev Neurother; 2011 Dec; 11(12):1673-81. PubMed ID: 22091592
[TBL] [Abstract][Full Text] [Related]
26. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
27. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
[TBL] [Abstract][Full Text] [Related]
28. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.
Hebeisen S; Pires N; Loureiro AI; Bonifácio MJ; Palma N; Whyment A; Spanswick D; Soares-da-Silva P
Neuropharmacology; 2015 Feb; 89():122-35. PubMed ID: 25242737
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
[TBL] [Abstract][Full Text] [Related]
30. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Lattanzi S; Trinka E; Zaccara G; Striano P; Russo E; Del Giovane C; Silvestrini M; Brigo F
Drugs; 2022 Feb; 82(2):199-218. PubMed ID: 35061214
[TBL] [Abstract][Full Text] [Related]
31. Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review.
Rissardo JP; Caprara ALF
Clin Neuropharmacol; 2020; 43(3):66-80. PubMed ID: 32384309
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.
Gil-Nagel A; Lopes-Lima J; Almeida L; Maia J; Soares-da-Silva P;
Acta Neurol Scand; 2009 Nov; 120(5):281-7. PubMed ID: 19832771
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of eslicarbazepine: current evidence.
Zaccara G; Giovannelli F; Cincotta M; Carelli A; Verrotti A
Drug Des Devel Ther; 2015; 9():781-9. PubMed ID: 25709402
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Patsalos PN; Berry DJ
Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
36. Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy.
Li-Na Z; Deng C; Hai-Jiao W; Da X; Ge T; Ling L
Epilepsy Res; 2018 Jan; 139():60-72. PubMed ID: 29197667
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and drug interactions of eslicarbazepine acetate.
Bialer M; Soares-da-Silva P
Epilepsia; 2012 Jun; 53(6):935-46. PubMed ID: 22612290
[TBL] [Abstract][Full Text] [Related]
38. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
Chang XC; Yuan H; Wang Y; Xu HQ; Zheng RY
Cochrane Database Syst Rev; 2011 Dec; (12):CD008907. PubMed ID: 22161441
[TBL] [Abstract][Full Text] [Related]
39. Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
Lattanzi S; Cagnetti C; Foschi N; Lorusso A; Provinciali L; Silvestrini M
Acta Neurol Scand; 2018 Jan; 137(1):29-32. PubMed ID: 28741673
[TBL] [Abstract][Full Text] [Related]
40. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.
Peltola J; Holtkamp M; Rocamora R; Ryvlin P; Sieradzan K; Villanueva V
Epilepsy Behav; 2015 Sep; 50():46-9. PubMed ID: 26114438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
